drugset / Trial / NCT02922777
Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.
Phase 1
Completed
23 enrolled
University of Texas Southwestern Medical Center
BerGenBio ASA · collabTexas Tech University Health Sciences Center · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is being done to evaluate the safety of the investigational study drug, BGB324 when administered in combination with docetaxel, and to establish the maximum tolerated dose.
Timeline
- Start
- 2016-11
- Primary completion
- 2023-02-06
- Completion
- 2023-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bemcentinib | Small molecule | 75 mg/m2 | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |